Stocks to Watch Today (November 14, 2025): TMPV, Infosys, ONGC, Websol Energy System, TMCV, Bharat Dynamics and more

Stocks to Watch Today (November 14, 2025): Indian equities are set for a busy session on Friday with multiple earnings announcements, corporate actions, and sector-specific developments likely to guide market sentiment. Several Nifty and F&O companies will remain in focus as investors track quarterly results, ex-date triggers, and record-date updates.

– Max Healthcare

– Tata Motors Passenger Vehicles

– Exide Industries

– Glenmark Pharma

– Inox Wind

– Oil India

– TVS Holdings

– The stock will shift from the T2T segment to the rolling segment.

– ONGC: Interim dividend of Rs 6 per share

– Petronet LNG: Interim dividend of Rs 7 per share

– National Aluminium: Interim dividend of Rs 4 per share

– Websol Energy System: Stock split from Rs 10 to Rs 1

– Infosys: Share buyback (Offer size: Rs 18,000 crore; Buyback price: Rs 1,800)

– GHCL Ltd: Buyback (Offer size: Rs 300 crore; Buyback price: Rs 725)

– Allcargo Terminals: Rights issue (24 Nov–9 Dec; Issue size: Rs 80 crore; Price: Rs 20; Ratio: 3 rights shares for every 19 shares held)

– Weak headline numbers; adjusted performance strong

– Tata Motors Commercial Vehicles posted mixed Q2FY26 results.

– Revenue rose 5.9 per cent to Rs 18,585 crore.

– EBITDA fell sharply to Rs 17 crore from Rs 1,707 crore.

– Margin contracted to 0.09 per cent from 9.7 per cent.

– The company reported a loss of Rs 867 crore against a profit of Rs 498 crore last year.

– A fair value loss of Rs 2,027 crore by a subsidiary impacted the bottom line.

– Adjusted (press-release) performance

– EBITDA at Rs 2,200 crore, up 21 per cent.

– Margin improved to 12.2 per cent from 10.7 per cent.

– The company expects a strong H2FY26. Domestic CV volumes rose 9 per cent YoY, while exports surged 75 per cent. Market share remained steady at 35.3 per cent in H1FY26.

– Bharat Dynamics reported robust Q2FY26 performance.

– Revenue jumped 110.6 per cent to Rs 1,147 crore.

– EBITDA rose 89.7 per cent to Rs 187.5 crore.

– PAT increased 76.2 per cent to Rs 215.9 crore.

– The Ministry of Defence signed a Rs 2,095-crore contract with the company for INVAR anti-tank missiles.

– In line with estimates; record revenue and PAT

– Revenue up 15.9 per cent at Rs 12,126 crore.

– EBITDA up 20.2 per cent at Rs 1,823 crore.

– Margin steady at 15 per cent.

– PAT up 15.7 per cent at Rs 1,393 crore.

– The company gained market share and continued expanding its EV portfolio.

– Revenue up 15.8 per cent to Rs 1,699 crore.

– EBITDA up 16.2 per cent to Rs 330 crore.

– PAT up 23 per cent to Rs 64 crore.

– Muthoot Finance posted strong numbers and raised its FY26 gold loan growth outlook to 30–35 per cent.

– NII up 58 per cent to Rs 3,992 crore.

– PAT up 87 per cent to Rs 2,345 crore.

– GNPA improved to 2.25 per cent; NNPA at 1.21 per cent.

– Gold assets grew 47 per cent YoY to Rs 1,32,305 crore, the highest ever.

– Gold holdings increased from 199 tonnes to 209 tonnes.

– Revenue down 2.4 per cent to Rs 655 crore.

– EBITDA down 47 per cent to Rs 30 crore.

– PAT fell 88 per cent to Rs 2 crore.

– Demand for room air-conditioners remained soft due to early monsoons and GST rate cut expectations. However, the order book remains healthy.

– Strong operating performance

– Revenue rose 47 per cent to Rs 3,669 crore.

– EBITDA up 59 per cent to Rs 1,531 crore.

– PAT at Rs 35 crore versus a loss of Rs 428 crore.

– The company reported its first positive PBT in over three years, with record EBITDA at Delhi and Hyderabad airports.

A block deal is likely as promoter entity Sagility BV may sell up to 16.4 per cent stake, valued at around Rs 3,550 crore. The floor price is Rs 46.4 per share, about 8 per cent below the current market price.

The government has withdrawn 14 BIS Quality Control Orders to improve raw material availability and ease import constraints for MSMEs in polymers, fibres, packaging, and moulding.

The company secured approval from the Odisha government to set up a renewable energy facility with an investment of Rs 4,500 crore, including solar cell and module units, battery manufacturing, and captive power.

– USFDA inspection of its Ahmedabad SEZ-1 unit concluded with two observations.

– The company received final approval for Diroximel Fumarate DR capsules (231 mg), used in treating multiple sclerosis in a market worth USD 999 million.

Received a Rs 340-crore order from the Central University of Kashmir.

Announced consolidation of multiple R&D and lab units in Mumbai and Baroda as part of its strategic growth plan.

Signed an agreement with the Andhra Pradesh government for a Rs 70-crore investment to expand dairy processing capacity and set up new Samadhan centres for oil palm farmers.